ZA200807667B - Use of inhibitors of Jun N-terminal kinases to treat glaucoma - Google Patents

Use of inhibitors of Jun N-terminal kinases to treat glaucoma

Info

Publication number
ZA200807667B
ZA200807667B ZA200807667A ZA200807667A ZA200807667B ZA 200807667 B ZA200807667 B ZA 200807667B ZA 200807667 A ZA200807667 A ZA 200807667A ZA 200807667 A ZA200807667 A ZA 200807667A ZA 200807667 B ZA200807667 B ZA 200807667B
Authority
ZA
South Africa
Prior art keywords
jun
inhibitors
treat glaucoma
terminal kinases
kinases
Prior art date
Application number
ZA200807667A
Other languages
English (en)
Inventor
Debra L Fleenor
Iok-Hou Pang
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of ZA200807667B publication Critical patent/ZA200807667B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA200807667A 2006-03-31 2007-03-14 Use of inhibitors of Jun N-terminal kinases to treat glaucoma ZA200807667B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/394,893 US7803824B2 (en) 2004-10-29 2006-03-31 Use of inhibitors of Jun N-terminal kinases to treat glaucoma

Publications (1)

Publication Number Publication Date
ZA200807667B true ZA200807667B (en) 2010-07-28

Family

ID=38523463

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200807667A ZA200807667B (en) 2006-03-31 2007-03-14 Use of inhibitors of Jun N-terminal kinases to treat glaucoma

Country Status (13)

Country Link
US (3) US7803824B2 (zh)
EP (1) EP2004158A2 (zh)
JP (1) JP5241033B2 (zh)
KR (1) KR20080108503A (zh)
CN (1) CN101415407B (zh)
AR (1) AR060222A1 (zh)
AU (1) AU2007235111B2 (zh)
BR (1) BRPI0710099A2 (zh)
CA (1) CA2644721A1 (zh)
MX (1) MX2008011319A (zh)
TW (1) TWI419694B (zh)
WO (1) WO2007117849A2 (zh)
ZA (1) ZA200807667B (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803824B2 (en) * 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma
US20060094753A1 (en) * 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
US20090202524A1 (en) * 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders
US20100056609A1 (en) * 2008-08-26 2010-03-04 Washington University Methods and compositions for inhibition of axonal degeneration by modulation of the dlk/jnk pathway
US20120077753A1 (en) * 2009-06-25 2012-03-29 Laxman Gangwani Jnk inhibitors for use in treating spinal muscular atrophy
AU2012224653A1 (en) * 2011-03-07 2013-10-03 Fondazione Telethon TFEB variants and uses thereof
AU2014301631A1 (en) * 2013-06-26 2015-08-27 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
EP3160489B9 (en) * 2014-06-26 2023-10-04 Xigen Inflammation Ltd. Cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of cystitis

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0840617B1 (en) * 1996-04-26 2008-06-18 University Of Ottawa Use of naip or iap for the treatment and prevention of neuronal disease
US6451787B1 (en) * 1998-10-13 2002-09-17 Cephalon, Inc. Remedies for ocular diseases
ES2209527T3 (es) 1998-12-17 2004-06-16 F. Hoffmann-La Roche Ag "44- y 5-alquiniloxindolels y 4- y 5-alqueniloxindones.
WO2000064872A1 (en) 1999-04-23 2000-11-02 Vertex Pharmaceuticals Incorporated INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK)
DE60039616D1 (de) 1999-08-13 2008-09-04 Vertex Pharma INHIBITOREN DER c-JUN N-TERMINALEN KINASE (JNK) UND ANDERE PROTEIN-KINASEN
NZ517578A (en) 1999-08-19 2004-02-27 Signal Pharm Inc Pyrazoloanthrone and derivatives thereof as JNK inhibitors and their compositions
US20040072888A1 (en) * 1999-08-19 2004-04-15 Bennett Brydon L. Methods for treating inflammatory conditions or inhibiting JNK
EP1088815A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl amino acid derivatives
EP1088822A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl hydrazide derivatives
EP1088821A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives
EP1110957A1 (en) 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
JP2003535062A (ja) 2000-06-01 2003-11-25 メルク エンド カムパニー インコーポレーテッド Ｊｎｋ阻害剤としての（二置換フェニル）ピリミジニルイミダゾール誘導体の使用
EP1193256A1 (en) 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active benzsulfonamide derivatives as inhibitors of JNK proteins
US7129242B2 (en) 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
EP1364949A4 (en) 2001-02-02 2005-11-23 Takeda Pharmaceutical INHIBITOR OF JNK
GB0108770D0 (en) 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
US6982274B2 (en) 2001-04-16 2006-01-03 Eisai Co., Ltd. 1H-indazole compound
US20040254189A1 (en) 2001-08-23 2004-12-16 Hideaki Nagaya Jnk inhibitors
MXPA04002243A (es) 2001-09-19 2004-06-29 Aventis Pharma Sa Compuestos quimicos.
JP2003129190A (ja) 2001-10-19 2003-05-08 Sumitomo Metal Ind Ltd マルテンサイト系ステンレス鋼およびその製造方法
US20030138819A1 (en) 2001-10-26 2003-07-24 Haiqing Gong Method for detecting disease
US7390797B2 (en) * 2002-02-28 2008-06-24 Eisai Co., Ltd. Fused indazole compounds
MXPA04009471A (es) * 2002-04-30 2005-01-25 Alcon Inc Agentes que regulan, inhiben o modulan la actividad y/o expresion de factor de crecimiento de tejido de conexion (ctgf) como un medio unico para ambos reducir la presion intraocular y tratar retinopatias glaucomatosas/neuropatias opticas.
JP4662764B2 (ja) 2002-06-14 2011-03-30 メルク セローノ ソシエテ アノニム アゾールメチリデンシアニド誘導体およびそれらのタンパク質キナーゼモジュレーターとしての使用
KR20050057175A (ko) * 2002-09-20 2005-06-16 알콘, 인코퍼레이티드 안구건조증 치료용 사이토카인 합성 저해제의 용도
US20040092568A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods for the treatment, prevention and management of macular degeneration
US20060094753A1 (en) 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
US7803824B2 (en) * 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma
US20060275797A1 (en) * 2005-03-21 2006-12-07 Alcon Manufacturing, Ltd. Use of agents which inhibit connective tissue growth factor (CTGF) binding and signaling via the TrkA/p75NTR receptor complex for the prevention and treatment of CTGF-mediated ocular disorders

Also Published As

Publication number Publication date
US7803824B2 (en) 2010-09-28
EP2004158A2 (en) 2008-12-24
AU2007235111B2 (en) 2012-03-22
US20060172991A1 (en) 2006-08-03
MX2008011319A (es) 2008-09-19
TWI419694B (zh) 2013-12-21
TW200744601A (en) 2007-12-16
WO2007117849A3 (en) 2008-04-10
CA2644721A1 (en) 2007-10-18
AU2007235111A1 (en) 2007-10-18
CN101415407A (zh) 2009-04-22
AR060222A1 (es) 2008-06-04
JP5241033B2 (ja) 2013-07-17
KR20080108503A (ko) 2008-12-15
US20100311716A1 (en) 2010-12-09
JP2009532373A (ja) 2009-09-10
CN101415407B (zh) 2011-05-11
US20120004274A1 (en) 2012-01-05
BRPI0710099A2 (pt) 2011-08-02
WO2007117849A2 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
IL263237A (en) Use of complement pathway inhibitors to treat eye diseases
HK1226071A1 (zh) 激酶抑制劑的組合物及其在治療癌症與其與激酶相關的疾病中的用途
EP2026843A4 (en) THERAPEUTIC USES OF RTP801L INHIBITORS
IL207609A0 (en) Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
IL232786A0 (en) Inhibitors of e1 enzyme activators
HK1167655A1 (zh) -末端激酶抑制劑
IL208719A0 (en) Inhibitors of protein kinases
ZA200807667B (en) Use of inhibitors of Jun N-terminal kinases to treat glaucoma
EP2278969A4 (en) INHIBITORS OF JANUS KINASES
EP1981888A4 (en) TYROSINE KINASE INHIBITORS AND USES THEREOF
HK1160607A1 (zh) 用於治療乾眼症和其它與眼相關疾病的 激酶
IL211835A0 (en) Therapeutic uses of inhibitors of rtp801
ZA200806871B (en) Dihydrodiazepines useful as inhibitors of protein kinases
EP2310384A4 (en) INHIBITORS OF KINASES JANUS
EP2341775A4 (en) INHIBITORS OF JANUS KINASES
EP2323659A4 (en) COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES
EP2242501A4 (en) THERAPEUTIC INHIBITORS OF PAI-I FUNCTION AND METHODS OF USE
IL195722A0 (en) Therapeutic uses of inhibitors of rtp801l